Shaperon Inc.
KKRX:3788002,335.00
KRW
+35.00
(+1.52%)
ISIN
KR7378800007
Return %
Stock
S&P 500
1Y
-80.34
13.14
3Y
-85.47
80.78
5Y
- -
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Seung-Yong Sung
- Full Time Employees
- 53
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Seoul South Korea
- IPO Date
- Oct 19, 2022
- Website
- shaperon.com
- Similar Companies
- Business
- Shaperon Inc. is a South Korea-based clinical-stage biopharmaceutical company engaged in the research, development, and commercialization of novel therapeutics for inflammatory, autoimmune, and oncological diseases. Founded in 2008 and headquartered in Seoul, South Korea, the company develops drug candidates utilizing two proprietary core technology platforms: a G-protein coupled receptor 19 (GPCR19)-mediated inflammasome inhibition platform that suppresses both the priming and activation stages of the NLRP3 inflammasome complex; and a single-domain camelid antibody platform, known as NanoMab, designed to engineer bispecific and multi-target nanobody therapeutics. The company's core product and development pipeline comprises: NuGel (HY209 gel), a topical inflammasome inhibitor formulation indicated for the treatment of moderate-to-severe atopic dermatitis; NuSepin (HY209 injection), an intravenous anti-inflammatory candidate developed for severe systemic inflammatory conditions, including sepsis, acute respiratory distress syndrome, and viral pneumonia; NuCerin (HY209 oral), an orally administered inflammasome inhibitor targeting neuroinflammatory conditions such as Alzheimer's disease; and nanobody-based oncology candidates, including bispecific immune checkpoint inhibitors targeting tumor antigens and immune modulators such as PD-L1 and CD47 for solid tumors and hematological malignancies. In recent strategic and operational developments, Shaperon Inc. established a United States subsidiary, Hudson Therapeutics, to manage global clinical development and commercial licensing partnerships. The company received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) and initiated global Phase 2b clinical trials for NuGel in patients with atopic dermatitis across multiple clinical sites in the United States. Furthermore, Shaperon has expanded its strategic collaborations with domestic and international biopharmaceutical companies to co-develop bispecific nanobody drugs, and completed financing initiatives to support its ongoing multinational clinical programs and pipeline advancement.